Edition:
United Kingdom

Predictive Technology Group Inc (PRED.PK)

PRED.PK on OTC Markets Group

2.80USD
19 Jul 2019
Change (% chg)

$0.30 (+12.00%)
Prev Close
$2.50
Open
$2.55
Day's High
$2.91
Day's Low
$2.55
Volume
708,476
Avg. Vol
492,270
52-wk High
$6.91
52-wk Low
$0.77

Summary

Name Age Since Current Position

John Sorrentino

2018 Chairman of the Board

Bradley Robinson

40 2018 President, Chief Executive Officer, Director

Simon Brewer

Chief Financial Officer

Paul Evans

Chief Operating Officer

Eric Kenneth Olson

Executive Vice President of PRED and CEO of Predictive Biotech

Michael Herbert

Chief Marketing Officer

John Nelson

2018 Chief Medical Officer

Ronald Barhorst

2019 Director

Michael Dey

2018 Director, Chief Executive Officer of Predictive Therapeutics

Orrin Hatch

85 2019 Director

Jay Moyes

64 2019 Independent Director

Jody Cain

2018 IR Contact Officer

Biographies

Name Description

John Sorrentino

Mr. John Sorrentino is Chairman of the Board of the Company. Sorrentino brings vast experience in R&D, commercialization and clinical laboratory management and has served in leadership positions in public and private companies. Prior to joining Wyeth/Pfizer 15 years ago, he held executive positions in several organizations that provided neonatal screening and related clinical services. Sorrentino is a noted expert in the healthcare industry, having presented to state legislatures, the U.S. Congress and professional societies on a variety of healthcare and policy issues. Sorrentino has more than 35 years of senior management experience in the life sciences industry and serves as Vice President and Chief Operating Officer of Pfizer Vaccine Research and Development.

Bradley Robinson

Mr. Bradley C. Robinson serves as President, Chief Executive Officer, Director of the Company. Previously President, Sagent Technologies (medical device division of Sagent Pharmaceuticals), CEO/Co-Founder of Infusive Technologies (developer of drug delivery technologies) and Director/Co-Founder of Specialized Health Products, Inc., acquired by C.R. Bard, Inc. Mr. Robinson studied accounting at the University of Utah and received a Masters of International Management from the Thunderbird, The American Graduate School of International Management.

Simon Brewer

Mr. Simon Brewer serves as Chief Financial Officer of the Company. He is responsible for Predictive’s finance, and accounting functions. Prior to Predictive, Simon served as Chief Financial Officer of Norbest, joined in 2016. He was responsible for Norbest’s finance, accounting, HR and IT functions. Norbest employs just over 500 people having annual sales around $150 million with products being sold in the United States and numerous foreign countries through international distribution. Mister Brewer has served as Vice President, Finance and IT for Wilson Electronics, LLC, in St. George, UT, where he was responsible for their finance, IT and HR functions. Earlier in his career he held the position as Senior Director and Corporate Controller for Backcountry.com, Inc. Simon started his accounting career as an Auditor for KPMG LLP, with clients ranging from non-profits to $20 billion conglomerates. Simon received his bachelor’s degree in Accounting, and a minor in Russian, from the University of Utah in Salt Lake City, Utah in 2004. He completed his Masters of Accounting at the same school in 2005. He has been a Certified Public Accountant since 2006.

Paul Evans

Mr. Paul Evans serves as Chief Operating Officer of the Company. Mr. Paul Evans was previously the head of all intellectual property matters for Vivint. He brings his expertise on Complex Transaction Negotiation and FDA regulatroy compliance to Predictive.

Eric Kenneth Olson

Mr. Eric Kenneth Olson serves as Executive Vice President of PRED and CEO of Predictive Biotech of the Company. Eric Kenneth Olson is the Executive Vice President of Predictive Technology Group, and the Founder and Chief Executive Officer of Predictive Biotech, Inc. Mr. Olson’s previous experience includes over 25 years developing and commercializing innovative technologies in devices, diagnostics, biologics and biomaterials. Prior to joining Predictive Technology Group, Mr. Olson was the President and CEO of Skeletal Kinetics which developed and commercialized synthetic bone substitute products for Orthopedic and Spinal applications. Previous to that, Mr. Olson was the President, CEO and Board Member for Amedica Corporation. Amedica manufactured devices for spine. In addition, the company distributed a line of HCT/Ps designed to work in conjunction with the ceramic biomaterial. Mr. Olson took Amedica Corporation public in 2014. Mr. Olson previously held roles with Smith & Nephew, Johnson & Johnson, Medtronic and Wright Medical in Sales and Marketing leadership. Mr. Olson earned his BS in Behavioral Science and Health Administration degrees from The University of Utah.

Michael Herbert

Mr. Michael Herbert serves as Chief Marketing Officer of the Company. A marketing and sales master for over 25 years, Michael Herbert brings his special brand of creativity and wit to the Predictive team. Driven by an entrepreneurial spirit, he specializes in business start-ups, product packaging and consumer experience. Michael’s previous experience includes ownership and leadership positions with some of the consumer sporting goods channels most revered brands. Creating and driving the global marketing, brand strategy and sales effectively drove Bianchi bicycles, Castelli apparel and Shock Doctor to the top position in their category and markets. Herbert helps our clients craft internal /external messaging, marketing structure and rollout and product positioning. Michael spends plenty of time outdoors, whether cycling, fly fishing or skiing. He serves on two non-profit boards, and is active in the community

John Nelson

Dr. John C. Nelson. M.D., M.P.H serves as Chief Medical Officer of the Company. Dr. Nelson an obstetrician and gynecologist from Salt Lake City, Utah, brings a wealth of experience to PRED. Predictive Technology Group, Inc., specializes in genetic testing, diagnostics, and therapeutic products to advance precision medicine. Dr. Nelson served as President of the American Medical Association, Salt Lake County Medical Society, and the Utah Medical Association. Also, he chaired the Finance and Planning Committee of the World Medical Association. He served on the Advisory Committee to the Director of the National Institutes of Health (NIH), as well as, on the advisory committee for the Agency for Healthcare Research and Quality (AHRQ). As a spokesperson for the American Medical Association Alliance, he lectured on detecting and preventing interpersonal violence. Dr. Nelson became a charter member of the Prospective Payment Assessment Commission (ProPAC), now known as MedPAC. Dr. Nelson received numerous awards, among which are the Alumnus of the Year at Utah State University, the Distinguished Service Award from the University of Utah School of Medicine, the Emeritus Merit of Honor Award from the University of Utah Alumni Association, and the Light of Learning Award from the Utah Department of Education. As a founding co-chair of the Commission to End Healthcare Disparities, Dr. Nelson received a Lifetime Service Award from the National Medical Association. Dr. Nelson’s civic involvement includes time on the advisory committee of the local Boys and Girls Club of Salt Lake City, the Christmas Box House board, and the board of Operation Kids.

Ronald Barhorst

Mr. Ronald Barhorst is Director of the company. Mr. Barhorst is chair of The California State University Foundation. He is retired as president and chief executive officer of ING Financial Advisers, LLC and ING Investment Advisors, LLC and Systematized Benefits Administrators, Inc. He was also head of national accounts, healthcare and government markets. He previously served as director of residential services for Montgomery County Board of Mental Retardation and Development Disabilities and as treasurer for the Ohio Private Residential Services Association and Executive Director of Choices in Community Living, a non-profit organization he developed. Mr. Barhorst has served on numerous non-profit boards, including the California Business Roundtable for Education Excellence.

Michael Dey

Mr. Michael Dey is Director, Chief Executive Officer of Predictive Therapeutics of the Company. Dr. Dey will assist in corporate governance and guide the development and commercialization of technology and products in all PRED’s subsidiaries. In addition to serving as a PRED Board Member, Dr. Dey will continue as Chief Executive Officer of Predicitive Therapeutics, Inc., a wholly owned subsidiary of PRED. Before joining PRED, Dr. Dey had executive positions at Wyeth, later acquired by Pfizer, where he was both the President and the President of Scientific Affairs division for Wyeth’s Women’s Health Care business. As President of Wyeth’s Women’s Health Care business for seven years, Dr. Dey managed its global resources of more than $3 billion annually. Dr. Dey received an undergraduate degree in Biology/Chemistry in 1973, a Master’s Degree in 1980 in Pharmacology and Toxicology and a Ph.D. in 1984 in Pharmacology and Toxicology.

Orrin Hatch

Sen. Orrin G. Hatch is Director of the company. Hatch is an attorney and retired politician who served as a U.S. Senator from Utah for 42 years. First elected in 1976, he was the longest-serving Republican U.S. Senator in history. Senator Hatch served as either the chair or ranking minority member of the Senate Judiciary Committee from 1993 to 2005. He previously chaired the Senate Committee on Health, Education, Labor, and Pensions from 1981 to 1987. Senator Hatch also served as Chairman of the Senate Finance Committee. On January 3, 2015, after the 114th United States Congress was sworn in, Hatch became President pro tempore of the Senate. Senator Hatch retired from the U.S. Senate in 2019.

Jay Moyes

Mr. Jay M. Moyes is Independent Director of the Company. Moyes previously served as Chief Financial Officer and Director of the publicly traded biomaterials company Amedica Corporation, now SINTX Technologies, where he managed the company's IPO and listing on NASDAQ, and as Chief Financial Officer at publicly traded CareDx, a molecular diagnostics company where he introduced a strategy to reach profitability. Prior to that he held senior finance positions including Chief Financial Officer during his 14-year tenure at publicly traded Myriad Genetics. In addition to overseeing all financial aspects at Myriad as the company transitioned from 10 to more than 900 employees, he was instrumental in raising more than $500 million in public and private financings. He previously was Vice President of Finance and Chief Financial Officer of Genmark, a private genetics company. Moyes began his career in public accounting at KPMG.

Jody Cain